- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Treatment of Waldenström Macroglobulinemia
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-19
DOI
10.1007/s11912-023-01459-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Rory Morrison WMUK Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorder
- (2023) Encarl Uppal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
- (2023) Suzanne O. Arulogun et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
- (2023) Christian Buske et al. JOURNAL OF CLINICAL ONCOLOGY
- CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
- (2022) M Lia Palomba et al. Journal for ImmunoTherapy of Cancer
- Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
- (2022) Naohiro Sekiguchi et al. CANCER SCIENCE
- Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.
- (2022) Jithma P. Abeykoon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
- (2022) Jorge J. Castillo et al. BLOOD
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- (2021) Anthony R Mato et al. LANCET
- Assessment of Fixed‐Duration Therapies for Treatment‐Naïve Waldenström Macroglobulinemia
- (2021) Jithma P. Abeykoon et al. AMERICAN JOURNAL OF HEMATOLOGY
- WhiMSICAL : A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomes
- (2021) Ibrahim Tohidi‐Esfahani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Matthew J Matasar et al. LANCET ONCOLOGY
- Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
- (2021) Cécile Tomowiak et al. Blood Advances
- Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia
- (2021) Steven P. P Treon et al. BLOOD
- Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
- (2021) Marie José Kersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) treated with CLR 131.
- (2021) Sikander Ailawadhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
- (2021) Jorge J. Castillo et al. LEUKEMIA
- Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations
- (2021) Steven P. Treon et al. BLOOD
- Venetoclax in Previously Treated Waldenström Macroglobulinemia
- (2021) Jorge J. Castillo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
- (2021) Christian Buske et al. JOURNAL OF CLINICAL ONCOLOGY
- CXCR4 mutational status does not impact outcomes in patients with W aldenström macroglobulinemia treated with proteasome inhibitors
- (2020) Jorge J. Castillo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
- (2020) Mathias J Rummel et al. BLOOD
- Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
- (2020) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up
- (2020) Judith Trotman et al. BLOOD
- Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
- (2020) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
- (2020) Jorge J. Castillo et al. Blood Advances
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
- (2020) Meletios Dimopoulos et al. Blood Advances
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
- (2019) Roger G Owen et al. Lancet Haematology
- Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
- (2018) Jonas Paludo et al. ANNALS OF HEMATOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
- (2018) Jorge J. Castillo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia
- (2018) Jad Othman et al. HAEMATOLOGICA
- Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia
- (2018) Jad Othman et al. HAEMATOLOGICA
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
- (2018) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)
- (2018) Kamel Laribi et al. BRITISH JOURNAL OF HAEMATOLOGY
- BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
- (2016) Maria Gavriatopoulou et al. BLOOD
- HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
- (2016) G. Yang et al. BLOOD
- Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study
- (2015) E. Kastritis et al. BLOOD
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
- (2014) A. M. Roccaro et al. BLOOD
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now